ReviewBrain pathology (Zurich, Switzerland)2009
Immunotherapy of diffuse gliomas: biological background, current status and future developments.
Review in Brain pathology (Zurich, Switzerland), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 4,016 citations in OpenAlex.
- Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.Cancer immunology, immunotherapy : CII · 2012Trial
- Article
- STEAP3 is a prognostic biomarker that promotes glioma progression by regulating immune microenvironment and PI3K-AKT pathway.Cancer biomarkers : section A of Disease markers · 2023Article
- The Interplay of Four Main Pathways Recomposes Immune Landscape in Primary and Metastatic Gastroenteropancreatic Neuroendocrine Tumors.Frontiers in oncology · 2022Article
- Identification of CDKL3 as a critical regulator in development of glioma through regulating RRM2 and the JNK signaling pathway.Cancer science · 2021Article
- MEX3A contributes to development and progression of glioma through regulating cell proliferation and cell migration and targeting CCL2.Cell death & disease · 2021Article
- Glioma escape signature and clonal development under immune pressure.The Journal of clinical investigation · 2020Article
- Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma.Molecular neurobiology · 2020Review
- Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma.Cancer immunology, immunotherapy : CII · 2019Article
- MiR-205 suppresses epithelial-mesenchymal transition and inhibits tumor growth of human glioma through down-regulation of HOXD9.Bioscience reports · 2019Article
- Concise Review: Modulating Cancer Immunity with Hematopoietic Stem and Progenitor Cells.Stem cells (Dayton, Ohio) · 2019Review
- Combined intracavitary thermotherapy with iron oxide nanoparticles and radiotherapy as local treatment modality in recurrent glioblastoma patients.Journal of neuro-oncology · 2019Article
- Article
- Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach.Clinical Medicine Insights. Oncology · 2018Review
- Article
- BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-κB/MGMT signaling pathway.Oncology letters · 2017Article
- Engineering challenges for brain tumor immunotherapy.Advanced drug delivery reviews · 2017Review
- Antitumor activity of 7-O-succinyl macrolactin A tromethamine salt in the mouse glioma model.Oncology letters · 2017Article
- Suppression of PDCD4 mediated by the long non-coding RNA HOTAIR inhibits the proliferation and invasion of glioma cells.Oncology letters · 2016Article
- Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.Neuro-oncology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite aggressive multimodal treatment approaches, the prognosis for patients with diffuse gliomas remains disappointing. Glioma cells often extensively infiltrate in the surrounding brain parenchyma, a phenomenon that helps them to escape surgical removal, radiation exposure and chemotherapy. Moreover, conventional therapy is often associated with considerable local and systemic side effects. Therefore, the development of novel therapeutic approaches is essential to improve the outcome of these patients. Immunotherapy offers the opportunity to specifically target residual radio-and chemoresistant tumor cells without damaging healthy neighboring brain tissue. Significant progress has been made in recent years both in understanding the mechanisms of immune regulation in the central nervous system (CNS) as well as tumor-induced and host-mediated immunosuppression elicited by gliomas. In this review, after discussing the special requirements needed for the initiation and control of immune responses in the CNS, we focus on immunological phenomena observed in glioma patients, discuss different immunological approaches to attack glioma-associated target structures and touch on further strategies to improve the efficacy of immunotherapy of gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.